Discovery of Rho-kinase inhibitors by docking-based virtual screening

Molecular BioSystems

Volumn 9, Issue 6, 2013, Pages 1511-1521

  Shen, Mingyun ^a   Yu, Huidong ^a   Li, Youyong ^a   Li, Pixu ^a   Pan, Peichen ^a   Zhou, Shunye ^a   Zhang, Liling ^a   Li, Shang ^b   Lee, Simon Ming Yuen ^b   Hou, Tingjun ^a,c  

^a SOOCHOW UNIVERSITY   (China)

^b UNIVERSITY OF MACAU   (Macao)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; RHO KINASE; ROCK1 PROTEIN, HUMAN;

ANIMAL; ARTICLE; BRAIN HEMORRHAGE; BREAST TUMOR; CHEMICAL STRUCTURE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG ANTAGONISM; DRUG SCREENING; FEMALE; HELA CELL; HUMAN; LUNG TUMOR; METABOLISM; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; TUMOR CELL LINE; ZEBRA FISH; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CEREBRAL HEMORRHAGE; CHEMICALLY INDUCED; HELA CELL LINE; LUNG NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CEREBRAL HEMORRHAGE; DRUG EVALUATION, PRECLINICAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HELA CELLS; HEPTANOIC ACIDS; HUMANS; LUNG NEOPLASMS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; MOLECULAR STRUCTURE; MULTIPLE MYELOMA; PROTEIN KINASE INHIBITORS; PYRROLES; RHO-ASSOCIATED KINASES; ZEBRAFISH;

EID: 84877779750     PISSN: 1742206X     EISSN: 17422051     Source Type: Journal    
DOI: 10.1039/c3mb00016h     Document Type: Article

References (56)

1. T. Matsui M. Amano T. Yamamoto K. Chihara M. Nakafuku M. Ito T. Nakano K. Okawa A. Iwamatsu K. Kaibuchi Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho EMBO J. 1996 15 2208 2216
2. T. Leung E. Manser L. Tan L. Lim A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes J. Biol. Chem. 1995 270 29051 29054
3. O. Nakagawa K. Fujisawa T. Ishizaki Y. Saito K. Nakao S. Narumiya ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice FEBS Lett. 1996 392 189 193
4. M. F. Olson Applications for ROCK kinase inhibition Curr. Opin. Cell Biol. 2008 20 242 248
5. T. Force K. Kuida M. Namchuk K. Parang J. M. Kyriakis Inhibitors of protein kinase signaling pathways Circulation 2004 109 1196 1205
6. B. K. Mueller H. Mack N. Teusch Rho kinase, a promising drug target for neurological disorders Nat. Rev. Drug Discovery 2005 4 387 398
7. K. Kitamura S. Tada N. Nakamoto K. Toda H. Horikawa S. Kurita S. Tsunematsu N. Kumagai H. Ishii H. Saito Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis J. Gastroenterol. Hepatol. 2007 22 2022 2033
8. E. Sahai C. J. Marshall RHO-GTPases and cancer Nat. Rev. Cancer 2002 2 133 142
9. T. Kamai T. Yamanishi H. Shirataki K. Takagi H. Asami Y. Ito K. I. Yoshida Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer Clin. Cancer Res. 2004 10 4799 4805
10. Y. Nishimura K. Itoh K. Yoshioka K. Tokuda M. Himeno Overexpression of ROCK in human breast cancer cells: evidence that ROCK activity mediates intracellular membrane traffic of lysosomes Pathol. Oncol. Res. 2003 9 83 95
11. T. Kamai T. Tsujii K. Arai K. Takagi H. Asami Y. Ito H. Oshima Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer Clin. Cancer Res. 2003 9 2632 2641
12. C. C. L. Wong C. M. Wong E. K. K. Tung K. Man I. O. L. Ng Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion Hepatology 2009 49 1583 1594
13. S. Satoh T. Utsunomiya K. Tsurui T. Kobayashi I. Ikegaki Y. Sasaki T. Asano Pharmacological profile of hydroxy fasudil as a selective Rho kinase inhibitor on ischemic brain damage Life Sci. 2001 69 1441 1453
14. T. Ishizaki M. Uehata I. Tamechika J. Keel K. Nonomura M. Maekawa S. Narumiya Pharmacological properties of Y-27632, a specific inhibitor of Rho-associated kinases Mol. Pharmacol. 2000 57 976 983
15. M. Lohn O. Plettenburg Y. Ivashchenko A. Kannt A. Hofmeister D. Kadereit M. Schaefer W. Linz M. Kohlmann J. M. Herbert Pharmacological characterization of SAR407899, a novel Rho-kinase inhibitor Hypertension 2009 54 676 683
16. R. D. Williams G. D. Novack T. Van Haarlem C. Kopczynski Ocular Hypotensive Effect of the Rho kinase Inhibitor AR-12286 in Patients With Glaucoma and Ocular Hypertension Am. J. Ophthalmol. 2011 152 834 841
17. J. Chen S. A. Runyan M. R. Robinson Novel ocular antihypertensive compounds in clinical trials Clinical Ophthalmology 2011 5 667
18. L. McKerracher H. Higuchi Targeting Rho to stimulate repair after spinal cord injury J. Neurotrauma 2006 23 309 317
19. H. Shimokawa M. Rashid Development of Rho-kinase inhibitors for cardiovascular medicine Trends Pharmacol. Sci. 2007 28 296 302
20. J. K. Liao M. Seto K. Noma Rho kinase (ROCK) inhibitors J. Cardiovasc. Pharmacol. 2007 50 17
21. J. Qin B. Lei L. Xi H. Liu X. Yao Molecular modeling studies of Rho kinase inhibitors using molecular docking and 3D-QSAR analysis Eur. J. Med. Chem. 2010 45 2768 2776
22. K. Gohda T. Hakoshima A molecular mechanism of P-loop pliability of Rho-kinase investigated by molecular dynamic simulation J. Comput.-Aided Mol. Des. 2008 22 789 797
23. T. J. Hou X. J. Xu Recent development and application of virtual screening in drug discovery: An overview Curr. Pharm. Des. 2004 10 1011 1033
24. P. R. Menard R. A. Lewis J. S. Mason Rational screening set design and compound selection: cascaded clustering J. Chem. Inf. Model. 1998 38 497 505
25. W. P. Walters M. T. Stahl M. A. Murcko Virtual screening-an overview Drug Discovery Today 1998 3 160 178
26. J. Deng E. G. Feng S. Ma Y. Zhang X. F. Liu H. L. Li H. Huang J. Zhu W. L. Zhu X. Shen L. Y. Miao H. Liu H. L. Jiang J. Li Design and Synthesis of Small Molecule RhoA Inhibitors: A New Promising Therapy for Cardiovascular Diseases? J. Med. Chem. 2011 54 4508 4522
27. D. Huang U. Luthi P. Kolb K. Edler M. Cecchini S. Audetat A. Barberis A. Caflisch Discovery of Cell-Permeable Non-Peptide Inhibitors of beta-Secretase by High-Throughput Docking and Continuum Electrostatics Calculations J. Med. Chem. 2005 48 5108 5111
28. D. Ekonomiuk X.-C. Su K. Ozawa C. Bodenreider S. P. Lim Z. Yin T. H. Keller D. Beer V. Patel G. Otting A. Caflisch D. Huang Discovery of a Non-Peptidic Inhibitor of West Nile Virus NS3 Protease by High-Throughput Docking PLoS Neglected Trop. Dis. 2009 3 e356
29. P. Kolb D. Huang F. Dey A. Caflisch Discovery of kinase Inhibitors by High-Throughput Docking and Scoring Based on a Transferable Linear Interaction Energy Model J. Med. Chem. 2008 51 1179 1188
30. M. Jacobs K. Hayakawa L. Swenson S. Bellon M. Fleming P. Taslimi J. Doran The structure of dimeric ROCK I reveals the mechanism for ligand selectivity J. Biol. Chem. 2006 281 260
31. Schrödinger, version 9.0, Schrödinger, LLC, New York, NY, 2009
32. G. A. Kaminski R. A. Friesner J. Tirado-Rives W. L. Jorgensen Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides J. Phys. Chem. B 2001 105 6474 6487
33. T. Liu Y. Lin X. Wen R. N. Jorissen M. K. Gilson BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities Nucleic Acids Res. 2007 35 D198 D201
34. Discovery Studio 2.5 Guide, Accelrys Inc., San Diego, http://www.accelrys.com, 2009
35. J. M. Wang R. M. Wolf J. W. Caldwell P. A. Kollman D. A. Case Development and testing of a general amber force field J. Comput. Chem. 2004 25 1157 1174
36. V. Hornak R. Abel A. Okur B. Strockbine A. Roitberg C. Simmerling Comparison of multiple Amber force fields and development of improved protein backbone parameters Proteins: Struct., Funct., Bioinf. 2006 65 712 725
37. M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, J. A. J. Montgomery, T. Vreven, K. N. Kudin, J. C. Burant, J. M. Millam, S. S. Lyengar, J. Tomasi, V. Barone, B. Mennucci, M. Cossi, G. Scalmani, N. Rega, G. A. Petersson, H. Nakatsuji, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, M. Klene, X. Li, J. E. Knox, H. P. Hratchian, J. B. Cross, B. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, P. Y. Ayala, K. Morokuma, G. A. Voth, P. Salvador, J. J. Dannenberg, V. G. Zakrzewski, S. Dapprich, A. D. Daniels, M. C. Strain, O. Farkas, D. K. Malick, A. D. Rabuck, K. Raghavachari, J. B. Foresman, J. V. Ortiz, Q. Cui, A. G. Baboul, S. Clifford, J. Cioslowski, B. B. Stefanov, A. Liashenko, A. Liashenko, P. Piskorz, I. Komaromi, R. L. Martin, D. J. FOx, T. Keith, M. A. Al-Laham, C. Y. Peng, A. Nanayakkara, M. Challacombe, P. M. W. Gill, B. Johnson, W. Chen, M. W. Wong, C. Gonzalez and J. A. Pople, Gaussian 03, Gaussian Inc., Wallingford, CT, 2004
38. C. I. Bayly P. Cieplak W. D. Cornell P. A. Kollman A Well-Behaved Electrostatic Potential Based Method Using Charge Restraints for Deriving Atomic Charges-the Resp Model J. Phys. Chem. 1993 97 10269 10280
39. W. L. Jorgensen J. Chandrasekhar J. D. Madura R. W. Impey M. L. Klein Comparison of Simple Potential Functions for Simulating Liquid Water J. Chem. Phys. 1983 79 926 935
40. T. Darden D. York L. Pedersen Particle Mesh Ewald-an N·log(N) Method for Ewald Sums in Large Systems J. Chem. Phys. 1993 98 10089 10092
41. J. P. Ryckaert G. Ciccotti H. J. C. Berendsen Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes J. Comput. Phys. 1977 23 327 341
42. D. A. Case T. E. Cheatham T. Darden H. Gohlke R. Luo K. M. Merz A. Onufriev C. Simmerling B. Wang R. J. Woods The Amber biomolecular simulation programs J. Comput. Chem. 2005 26 1668 1688
43. T. J. Hou Z. Xu W. Zhang W. A. McLaughlin D. A. Case Y. Xu W. Wang Characterization of Domain-Peptide Interaction Interface: a generic structure-based model to decipher the binding specificity of SH3 domains Mol. Cell. Proteomics 2009 8 639 649
44. T. J. Hou W. Zhang D. A. Case W. Wang Characterization of domain-peptide interaction interface: A case study on the amphiphysin-1 SH3 domain J. Mol. Biol. 2008 376 1201 1214
45. H. Gohlke C. Kiel D. A. Case Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RaIGDS complexes J. Mol. Biol. 2003 330 891 913
46. T. Hou N. Li Y. Li W. Wang Characterization of Domain-peptide Interaction Interface: Prediction of SH3 Domain-Mediated Protein-protein Interaction Network in Yeast by Generic Structure-Based Models J. Proteome Res. 2012 11 2982 2995
47. T. Hou W. A. McLaughlin W. Wang Evaluating the potency of HIV-1 protease drugs to combat resistance Proteins: Struct., Funct., Bioinf. 2008 71 1163 1174
48. T. Hou J. Wang Y. Li W. Wang Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations J. Chem. Inf. Model. 2011 51 69 82
49. T. Hou J. Wang Y. Li W. Wang Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking J. Comput. Chem. 2011 32 866 877
50. T. Hou W. Zhang J. Wang W. Wang Predicting drug resistance of the HIV-1 protease using molecular interaction energy components Proteins: Struct., Funct., Bioinf. 2009 74 837 846
51. T. J. Hou Y. Y. Li W. Wang Prediction of peptides binding to the PKA RII alpha subunit using a hierarchical strategy Bioinformatics 2011 27 1814 1821
52. A. Onufriev D. Bashford A. David Modification of the generalized Born model suitable for macromolecules J. Phys. Chem. B 2000 104 3712 3720
53. S. Narumiya T. Ishizaki M. Ufhata Use and properties of ROCK-specific inhibitor Y-27632 Methods Enzymol. 2000 325 273 284
54. P. Ray J. Wright J. Adam J. Bennett S. Boucharens D. Black A. Cook A. R. Brown O. Epemolu D. Fletcher Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors Bioorg. Med. Chem. Lett. 2011 21 97 101
55. R. A. Stavenger H. Cui S. E. Dowdell R. G. Franz D. E. Gaitanopoulos K. B. Goodman M. A. Hilfiker L. Robert J. D. Leber J. P. Marino Jr Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity J. Med. Chem. 2007 50 2 5
56. ACD/ADME Suite 5.0, Advanced Chemistry Development Inc., Toronto, Canada, 2011